Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
D015761:4-Aminopyridine; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000549:Ambenonium Chloride / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D000242:Cyclic AMP / Q000502:physiology; D004491:Edrophonium / Q000627:therapeutic use; D004809:Ephedrine / Q000627:therapeutic use; D005861:Germine Acetates / Q000627:therapeutic use; D019791:Guanidine; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy*; D009388:Neostigmine / Q000627:therapeutic use; D009467:Neuromuscular Depolarizing Agents; D009469:Neuromuscular Junction / Q000502:physiology*; D011188:Potassium / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013569:Synapses / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects*
D000305:Adrenal Cortex Hormones; D000631:Aminopyridines; D002800:Cholinesterase Inhibitors; D005861:Germine Acetates; D006146:Guanidines; D009467:Neuromuscular Depolarizing Agents; D009388:Neostigmine; D000549:Ambenonium Chloride; D004491:Edrophonium; D000324:Adrenocorticotropic Hormone; D015761:4-Aminopyridine; D000242:Cyclic AMP; D004809:Ephedrine; D019791:Guanidine; D011729:Pyridostigmine Bromide; D011188:Potassium; D002118:Calcium